Effect of Antidepressants on Radiolabeled Metaiodobenzylguanidine (MIBG) Uptake by Werner, Rudolf et al.
Effect of Antidepressants on Radiolabeled Metaiodobenzylguanidine (MIBG) 
Uptake 
Rudolf A. Werner, Ryohei Kobayashi, Hiroshi Wakabayashi, Constantin Lapa, Andreas 
Menke, Takahiro Higuchi 
Background: Radiolabeled metaiodobenzylguanidine (MIBG) scintigraphy had been 
widely available not only for risk stratification of heart failure patients, but also for 
differential diagnosis of dementia with lewy bodies. Depression is one of the most 
common co-morbidities in such dementia patients. Pharmacological interference on 
cardiac 123I-MIBG uptake with conventional tricyclic antidepressants (TCA) via inhibiting 
norepinephrine transport is well recognized, but influence of the newly introduced 
antidepressants are not yet determined. 
Methods: In-vitro cell uptake assay using human neuroblastoma cells overexpressing 
NET (SK-N-SH cells (2*105 cells/well)) was conducted. Cells were incubated for 60 min 
at 37°C with 131I-MIBG together with three different antidepressants {desipramine 
(TCA), escitalopram (SSRI), venlafaxine (SNRI) or bupropion (NDRI)}. Dose-response 
curves were plotted to determine IC50 and % inhibition at Cmax (maximum concentrations 
determined at clinical trials). In healthy New Zealand White rabbits, in-vivo planar 10min 
123I-MIBG scans were performed 2.5 hours after intravenous 123I-MIBG administration 
(50MBq per animal). Imaging was conducted using 3 different pharmacological 
pretreatments 10min before tracer administration: 1) desipramine (1.5mg/kg weight IV), 
2) escitalopram (2.5 or 15 mg/kg weight IV) and 3) saline-treated controls. Heart-to-
mediastinum ratios (HMR) were calculated by dividing the count mediastinal ROI. 
Results: The IC50 value of desipramine, escitalopram, venlafaxine and bupropion on 
131I-MIBG uptake were 12 nM, 7.5 uM, 4.9 uM, and 13 uM, respectively. The inhibition 
rates of 131I-MIBG uptake were calculated as 90 % for desipramine, 0.7 % for 
escitalopram, 26 % for venlafaxine, and 12 % for bupropion at Cmax. Consisted with cell 
uptake study, desipramine pretreatment led to a marked reduction of the cardiac 123I-
MIBG uptake in-vivo (HMR: 1.94 ± 0.22 vs. 1.23 ± 0.13, p<0.01), while there was no 
significant pharmacological influence of escitalopram, even in blood concentrations 
being considerably higher than in clinical practice (escitalopram 2.5 mg/kg, HMR: 2.01 ± 
0.13, escitalopram 15 mg/kg, HMR: 2.05 ± 0.19, n.s. vs. controls). 
Conclusions: In the present in-vitro binding assay and in-vivo rabbit study, we 
demonstrated that serotonin selective antidepressant escitalopram (SSRI) has no major 
interference on neuronal 123I-MIBG uptake, while other types of antidepressants lead to 
a significant decrease.  
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